Merck & Co.'s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company's revenue, is raising investor concerns as the drug's patent expiration approaches in 2028 ...

Results have been announced from a Phase III trial of Merck & Co’s (NYSE: MRK) anti-PD-1 therapy Keytruda (pembrolizumab) plus Lenvima (lenvatinib), Eisai’s (TYO: 4523) orally available multiple ...

The com­bi­na­tion of Mer­ck’s Keytru­da and Ei­sai’s Lenvi­ma failed to pro­long pa­tients’ lives ver­sus the com­para­tor in an­oth­er can­cer study, but the com­pa­nies ...

Merck (NYSE:MRK) and Esai (OTCPK:ESALF) (OTCPK:ESAIY) announced Friday a mixed outcome in their Phase 3 LEAP-015 trial, which was designed to evaluate MRK’s anti-PD-1 therapy Keytruda and the Ja ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and Lenvima didn’t exactly go their way. The Keytruda-Lenvima regimen ...

Merck’s mega blockbuster Keytruda paired with Eisai’s Lenvima did not improve overall survival in a Phase III clinical trial of patients with an advanced form of gastroesophageal adenocarcinoma. While ...

Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve statistical significance for overall survival in patients with advanced ...

Immune checkpoint inhibitors have been the MVP of cancer drugs in recent years. Merck’s Keytruda, for example, has been used against dozens of different cancers in millions of patients ...

Prostate cancer has proved an elusive target for cancer immunotherapies, and Merck & Co's checkpoint inhibitor Keytruda is the latest to fall short in the disease in a phase 3 trial. Merck has ...

The price you pay for Keytruda may depend on factors such as your dosage and whether you have health insurance. Financial assistance may be available to help you with the cost of Keytruda.

Merck & Co's KEYNOTE-158 trial of Keytruda has underpinned another FDA approval, this time for the PD-1 inhibitor as a single-agent therapy as a therapy for endometrial cancer with certain genetic ...